12:00 AM
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Solanezumab: Phase III start

This quarter, Eli Lilly will begin the 18-month, double-blind, placebo-controlled, international EXPEDITION3 trial to evaluate 400 mg IV solanezumab every 4 weeks in 2,100 patients with mild AD who have tested positive for amyloid pathology on a PET scan or cerebrospinal fluid result. The pharma declined to disclose how much it expects the trial will cost.

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >